230 related articles for article (PubMed ID: 19757306)
1. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.
Coiffier B; Ribrag V
Leuk Lymphoma; 2009 Dec; 50(12):1916-30. PubMed ID: 19757306
[TBL] [Abstract][Full Text] [Related]
2. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
Hess G; Smith SM; Berkenblit A; Coiffier B
Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
[TBL] [Abstract][Full Text] [Related]
3. Temsirolimus for the treatment of mantle cell lymphoma.
Hess G
Expert Rev Hematol; 2009 Dec; 2(6):631-40. PubMed ID: 21082954
[TBL] [Abstract][Full Text] [Related]
4. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma.
Coiffier B
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):351-9. PubMed ID: 23763923
[TBL] [Abstract][Full Text] [Related]
6. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B
J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940
[TBL] [Abstract][Full Text] [Related]
9. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
10. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
11. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
Dancey JE; Curiel R; Purvis J
Semin Oncol; 2009 Dec; 36 Suppl 3():S46-58. PubMed ID: 19963100
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Rizzieri DA; Feldman E; Dipersio JF; Gabrail N; Stock W; Strair R; Rivera VM; Albitar M; Bedrosian CL; Giles FJ
Clin Cancer Res; 2008 May; 14(9):2756-62. PubMed ID: 18451242
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.
Witzig TE; Kaufmann SH
Curr Treat Options Oncol; 2006 Jul; 7(4):285-94. PubMed ID: 16916489
[TBL] [Abstract][Full Text] [Related]
14. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
[TBL] [Abstract][Full Text] [Related]
15. m-TOR inhibitors and their potential role in haematological malignancies.
Calimeri T; Ferreri AJM
Br J Haematol; 2017 Jun; 177(5):684-702. PubMed ID: 28146265
[TBL] [Abstract][Full Text] [Related]
16. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
Mounier N; Vignot S; Spano JP
Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
[TBL] [Abstract][Full Text] [Related]
17. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Panwalkar A; Verstovsek S; Giles FJ
Cancer; 2004 Feb; 100(4):657-66. PubMed ID: 14770419
[TBL] [Abstract][Full Text] [Related]
20. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
